The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
Therapy resistance mediated by cancer stem cells
TB Steinbichler, J Dudás, S Skvortsov… - Seminars in cancer …, 2018 - Elsevier
Cancer stem cells (CSC) possess abilities generally associated with embryonic or adult
stem cells, especially self-renewal and differentiation. The CSC model assumes that this …
stem cells, especially self-renewal and differentiation. The CSC model assumes that this …
Stem-cell aging and pathways to precancer evolution
CHM Jamieson, IL Weissman - New England Journal of Medicine, 2023 - Mass Medical Soc
Stem-Cell Aging and Pathways to Precancer Evolution | New England Journal of Medicine Skip
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
J Senapati, E Jabbour, H Kantarjian, NJ Short - Leukemia, 2023 - nature.com
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …
been a model for cancer therapy development. Though most patients with CML have a …
EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression
D Pradella, C Naro, C Sette, C Ghigna - Molecular cancer, 2017 - Springer
Epithelial-to-mesenchymal transition (EMT) is associated with metastasis formation as well
as with generation and maintenance of cancer stem cells. In this way, EMT contributes to …
as with generation and maintenance of cancer stem cells. In this way, EMT contributes to …
Chronic myeloid leukemia stem cells
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …
Stem cell plasticity and dormancy in the development of cancer therapy resistance
ML De Angelis, F Francescangeli, F La Torre… - Frontiers in …, 2019 - frontiersin.org
Cancer treatment with either standard chemotherapy or targeted agents often results in the
emergence of drug-refractory cell populations, ultimately leading to therapy failure. The …
emergence of drug-refractory cell populations, ultimately leading to therapy failure. The …
[HTML][HTML] Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons
EM Pietras, R Lakshminarasimhan… - The Journal of …, 2014 - ncbi.nlm.nih.gov
Type I interferons (IFN-1s) are antiviral cytokines that suppress blood production while
paradoxically inducing hematopoietic stem cell (HSC) proliferation. Here, we clarify the …
paradoxically inducing hematopoietic stem cell (HSC) proliferation. Here, we clarify the …
Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment
A Ludin, S Gur-Cohen, K Golan… - Antioxidants & redox …, 2014 - liebertpub.com
Significance: Blood forming, hematopoietic stem cells (HSCs) mostly reside in the bone
marrow in a quiescent, nonmotile state via adhesion interactions with stromal cells and …
marrow in a quiescent, nonmotile state via adhesion interactions with stromal cells and …
Targeting Bcl-2 for cancer therapy
L Zhang, Z Lu, X Zhao - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2021 - Elsevier
Apoptosis deficiency is one of the most important features observed in neoplastic diseases.
The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis …
The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis …